With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.59702-07-7,1-Methylpiperazin-2-one,as a common compound, the synthetic route is as follows.
4-(5-(4-(difluoromethoxy)phenyl)pyrimidin-2-ylamino)benzoic acid 54 (0.022 mmol), HATU (0.027 mmol) and l-methylpiperazin-2-one (0.022 mmol) are dissolved in dry DMF (0.5 mL) at rt. Diisopropylethylamine (0.06 mmol) is added to the solution. The reaction mixture is stirred for 1 h at rt. HPLC purification affords 4-(4-(5-(4-(difluoromethoxy)phenyl)pyrimidin-2-ylamino)benzoyl)- l-methylpiperazin-2-one Gl as a TFA salt. 1H NMR (400MHz, J6-DMSO) delta 10.1 (s, IH), 8.87 (s, 2H), 7.90 (d, J = 8.4 Hz, 2H), 7.79 (d, J = 8.7 Hz, 2H), 7.43 (d, J = 8.4Hz, 2H), 7.29 (d, J = 8.0 Hz, 2H), 7.12 (t, J = 51.2 Hz, IH), 4.1 (s, 2H), 2.87 (s, 3H), 2.55 (m, 4H). MS (m/z) (M+l)+: 454.2., 59702-07-7
As the paragraph descriping shows that 59702-07-7 is playing an increasingly important role.
Reference：
Patent; IRM LLC; WO2009/26276; (2009); A1;,
Piperazine – Wikipedia
Piperazines – an overview | ScienceDirect Topics